High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells (Q30433183)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells (English)

1 reference

Europe PubMed Central

21 August 2017

0 references

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

object named as

Brian D Peyser

24

0 references

object named as

Bryan T Mott

17

0 references

object named as

Adam Yasgar

8

0 references

object named as

Ajit Jadhav

23

0 references

27

object named as

Anton Simeonov

1 reference

Europe PubMed Central

21 August 2017

Christopher P Austin

25

object named as

Christopher P Austin

1 reference

Europe PubMed Central

21 August 2017

Craig J. Thomas

object named as

Craig J Thomas

30

1 reference

ORCID Public Data File 2021

15

object named as

Wenwei Huang

1 reference

Europe PubMed Central

21 August 2017

Andrew Paul Shinn

3

object named as

Paul Shinn

1 reference

Europe PubMed Central

21 August 2017

22

object named as

Ganesha Rai

1 reference

Europe PubMed Central

21 August 2017

Christopher A LeClair

21

object named as

Christopher A Leclair

1 reference

Europe PubMed Central

21 August 2017

Jian-kang Jiang

12

object named as

Jian-Kang Jiang

1 reference

Europe PubMed Central

21 August 2017

Lesley Mathews Griner

1

object named as

Lesley A Mathews Griner

1 reference

Europe PubMed Central

21 August 2017

2

object named as

Rajarshi Guha

1 reference

Europe PubMed Central

21 August 2017

author name string

Ryan M Young

4

1 reference

Europe PubMed Central

21 August 2017

Jonathan M Keller

5

1 reference

Europe PubMed Central

21 August 2017

Dongbo Liu

6

1 reference

Europe PubMed Central

21 August 2017

Ian S Goldlust

7

1 reference

Europe PubMed Central

21 August 2017

Crystal McKnight

9

1 reference

Europe PubMed Central

21 August 2017

Matthew B Boxer

10

1 reference

Europe PubMed Central

21 August 2017

Damien Y Duveau

11

1 reference

Europe PubMed Central

21 August 2017

Sam Michael

13

1 reference

Europe PubMed Central

21 August 2017

Tim Mierzwa

14

1 reference

Europe PubMed Central

21 August 2017

Martin J Walsh

16

1 reference

Europe PubMed Central

21 August 2017

Paresma Patel

18

1 reference

Europe PubMed Central

21 August 2017

William Leister

19

1 reference

Europe PubMed Central

21 August 2017

David J Maloney

20

1 reference

Europe PubMed Central

21 August 2017

Scott E Martin

26

1 reference

Europe PubMed Central

21 August 2017

Marc Ferrer

28

1 reference

Europe PubMed Central

21 August 2017

Louis M Staudt

29

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

27 January 2014

1 reference

Europe PubMed Central

21 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Proceedings of the National Academy of Sciences of the United States of America

1 reference

Europe PubMed Central

21 August 2017

111

1 reference

Europe PubMed Central

21 August 2017

2349-2354

1 reference

Europe PubMed Central

21 August 2017

6

1 reference

Europe PubMed Central

21 August 2017

Targeting pathological B cell receptor signalling in lymphoid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Combinatorial drug therapy for cancer in the post-genomic era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Systematic exploration of synergistic drug pairs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Oncogenically active MYD88 mutations in human lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Oncogenic activation of NF-kappaB.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Synergistic drug combinations tend to improve therapeutically relevant selectivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Combination chemical genetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Chemical combination effects predict connectivity in biological systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Gene expression profiling of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Systematic discovery of multicomponent therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926026

20 June 2018

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1311846111

21 January 2018

Isobolographic analysis for combinations of a full and partial agonist: curved isoboles

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1311846111

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24469833

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1073/PNAS.1311846111

1 reference

Europe PubMed Central

21 August 2017

2014PNAS..111.2349M

0 references

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30433183&oldid=2050344477"